CD151 Antibody

What is CD151 and what are its primary biological functions?

CD151 is a tetraspanin protein expressed on the surface of various cell types, including epithelial and endothelial cells. It plays critical roles in multiple cellular processes by forming complexes with other cell surface proteins. The primary functions of CD151 include:

• Regulation of cell adhesion through interactions with integrins (particularly α3β1, α6β1, and α6β4)

• Facilitation of cell migration and motility through membrane organization

• Modulation of cell proliferation and survival, especially in response to growth factors

• Formation of specialized microdomains on the plasma membrane called tetraspanin-enriched microdomains (TEMs)

• Participation in signaling pathways related to cancer progression and metastasis

CD151 is also known by several synonyms, including PETA-3 (Platelet-Endothelial tetra-span antigen) and Tspan-24, which may appear in older literature. The protein's involvement in multiple cellular processes makes CD151 antibodies valuable tools for studying both normal physiology and pathological conditions .

What experimental applications are suitable for CD151 antibodies?

CD151 antibodies can be utilized in diverse experimental applications, each providing unique insights into tetraspanin biology. The most common applications include:

For optimal results, researchers should select antibodies with validated reactivity in their experimental system and application of interest. Most CD151 antibodies used in research are mouse-derived monoclonal antibodies with IgG1 isotypes, such as clone 50-6 .

How should CD151 antibodies be validated before experimental use?

Thorough validation of CD151 antibodies is essential to ensure experimental reliability and reproducibility. A comprehensive validation protocol should include:

• Specificity testing: Compare signal in CD151-expressing versus CD151-negative or CD151-knockdown cells. RNAi-mediated silencing approaches have been successfully used to generate negative controls for CD151 antibody validation .

• Application-specific validation: Test the antibody in the specific application (WB, FC, ICC) intended for your experiment, as performance may vary across applications.

• Cross-reactivity assessment: Confirm specificity for CD151 versus other tetraspanin family members, particularly those with structural similarity.

• Functional validation: For blocking antibodies, confirm their ability to disrupt CD151-dependent functions such as cell-substrate adhesion or integrin-mediated migration.

• Reproducibility testing: Ensure consistent results across multiple experiments and different cell types expressing CD151.

When reporting research findings, it is advisable to include details of antibody validation to enhance experimental reproducibility and credibility of results. Studies have shown that CD151-specific antibodies can prevent tumor cell invasion and metastasis by modulating cell-substrate adhesion, demonstrating their potential as both research tools and therapeutic agents .

How do CD151 antibodies help elucidate the relationship between CD151 and integrin receptors?

CD151 forms tight associations with several integrin receptors, particularly α3β1, α6β1, and α6β4. CD151 antibodies have been instrumental in revealing these interactions and their functional significance through several methodological approaches:

• Co-immunoprecipitation studies: CD151 antibodies can be used to isolate CD151-integrin complexes from cell lysates prepared with mild detergents that preserve tetraspanin-enriched microdomains (TEMs). Research has shown that when CD151 is knocked down, β1 and β4 integrins cannot be co-purified with the residual tetraspanin, indicating complete functional knockout .

• Immunofluorescence co-localization: CD151 antibodies can visualize the spatial distribution of CD151 in relation to integrins on the cell surface, revealing their co-localization in specific membrane domains.

• Functional blocking studies: Certain CD151 antibodies can disrupt CD151-integrin interactions, allowing researchers to study the consequences on cell adhesion, migration, and signaling.

Analysis of CD151-integrin interactions requires careful consideration of detergent conditions. While CD151-β4 complexes can be maintained in mild detergents like Brij 97, they are disrupted by harsher detergents such as Triton X-100, highlighting the importance of experimental conditions when studying these interactions .

What role does CD151 play in Met-dependent signaling pathways and how can antibodies facilitate this research?

CD151 plays a critical role in HGF/Met signaling by facilitating the formation of signaling complexes between Met (the HGF receptor) and β4 integrin. CD151 antibodies can be valuable tools in studying these processes:

• Complex formation analysis: CD151 antibodies can isolate triple complexes containing Met, CD151, and β4 integrin from cancer cells. Research has shown that CD151 immunocomplexes contain both Met and β4 integrin, suggesting the formation of a ternary complex .

• Signaling pathway investigation: By using CD151 antibodies in combination with phospho-specific antibodies, researchers can monitor how CD151 affects Met-dependent signaling cascades. Studies have shown that CD151 depletion reduces HGF-triggered activation of MAPK but not AKT signaling cascade .

• Functional studies: Blocking CD151 antibodies can be used to disrupt Met-dependent tumor cell growth and survival, enabling researchers to assess the functional significance of these interactions.

Experimental evidence indicates that CD151 forms a molecular bridge between Met and β4 integrin, and this association occurs within cholesterol-enriched microdomains. When CD151 is depleted, the physical association between Met and β4 is disrupted, impairing HGF-induced phosphorylation of β4 integrin and subsequent signaling events .

How can CD151 antibodies be utilized in cancer research models?

CD151 antibodies have proven valuable in studying cancer progression and metastasis through various experimental approaches:

• Xenograft models: CD151 antibodies can be used to monitor CD151 expression in tumors derived from cancer cells injected into immunodeficient mice. Research has shown that CD151 knockdown significantly reduces HGF-driven tumor growth in vivo, suggesting that CD151 is required for Met-dependent tumorigenesis .

• Cell proliferation and survival assays: CD151 antibodies can assess how CD151 expression correlates with cancer cell proliferation and survival. Studies have demonstrated that the proliferative response to HGF is impaired in CD151-deficient cancer cells .

• Anchorage-independent growth assays: CD151 antibodies can evaluate the role of CD151 in soft agar colony formation, a hallmark of neoplastic transformation. Research has shown that CD151-deficient cells form significantly fewer foci upon HGF stimulation compared to control cells .

• Anoikis resistance studies: CD151 antibodies can monitor how CD151 contributes to cancer cell survival in the absence of attachment to the extracellular matrix. In anoikis assays using poly-HEMA-coated wells, HGF stimulation efficiently protects control cells but not CD151-deficient cells from cell death .

The connection between CD151 expression and cancer progression makes CD151 antibodies important tools in understanding tumor biology and potentially developing targeted therapies.

How can researchers optimize the use of CD151 antibodies for studying tetraspanin-enriched microdomains (TEMs)?

Tetraspanin-enriched microdomains (TEMs) are specialized membrane compartments that facilitate the assembly of protein complexes involved in cell signaling and adhesion. Studying these domains with CD151 antibodies requires specialized techniques:

• Detergent selection is critical: TEMs can only be isolated using mild membrane detergents such as Brij 97 or CHAPS. Research has confirmed that CD151-Met-β4 complexes can be recovered using mild detergents that preserve TEMs, whereas they are disrupted in the presence of Triton X-100 .

• Cholesterol dependency studies: Since TEMs may be affected by cholesterol depletion, researchers should consider using methyl-β-cyclodextrin treatment in conjunction with CD151 antibodies to assess the cholesterol dependency of specific interactions within TEMs.

• Membrane fractionation protocols: Sucrose gradient centrifugation combined with CD151 antibody detection can identify TEM-associated protein complexes in different membrane fractions.

• Proximity labeling approaches: Techniques like BioID or APEX2 proximity labeling, in combination with CD151 antibodies, can identify proteins that reside within or interact with TEMs.

• Super-resolution microscopy: Advanced imaging techniques (STORM, PALM, or STED) using fluorescently labeled CD151 antibodies can visualize the nanoscale organization of TEMs on the cell surface.

When designing experiments to study TEMs, researchers should be aware that these domains are distinct from prototypical lipid rafts but may share some properties. Cholesterol depletion can affect the distribution of certain tetraspanin-associated molecules, suggesting a complex organization of the cell surface .

What methodological considerations are important when using CD151 antibodies to study adhesion-dependent versus adhesion-independent functions?

CD151 has both adhesion-dependent and adhesion-independent functions, and distinguishing between these requires careful experimental design:

• Surface coating selection: For adhesion-dependent studies, researchers should use appropriate extracellular matrix components (like laminin or fibronectin) as substrates. Research has shown that CD151 down-regulation partly impairs integrin-dependent functions, especially cell adhesion and haptotactic migration on laminin substrates .

• Adhesion-blocking approaches: Specific CD151 antibodies can be used to block adhesion to matrix proteins without affecting other CD151 functions, allowing researchers to separate adhesive from non-adhesive roles.

• Suspension culture systems: For studying adhesion-independent functions, researchers can use:

  • Poly-HEMA-coated plates that prevent cell-substrate adhesion

  • Soft agar assays to evaluate anchorage-independent growth

  • Ultra-low attachment plates for anoikis studies

• Signal pathway analysis: CD151 antibodies can be used in combination with phospho-specific antibodies to distinguish between adhesion-dependent and adhesion-independent signaling events. Research has shown that CD151 is necessary to direct Met activity toward tyrosine phosphorylation of β4 integrin, triggering signaling pathways that lead to MAPK-regulated proliferative signals .

• Microscopy-based approaches: Live-cell imaging with fluorescently labeled CD151 antibodies can track CD151 localization during both adhesion-dependent and adhesion-independent processes.

Research has demonstrated that CD151 sustains adhesion-independent functions such as tumor cell growth in soft agar and protection from anoikis induced by HGF-Met signaling, challenges the conventional view that CD151 functions primarily through regulation of cell-substrate adhesion .

How can CD151 antibodies be used to investigate the contradictory roles of CD151 in tumor progression?

CD151's role in tumor progression is complex and sometimes contradictory, with evidence supporting both pro-tumorigenic and anti-tumorigenic functions. CD151 antibodies can help resolve these contradictions through carefully designed experiments:

• Context-dependent analysis: CD151 antibodies can be used to study CD151 function across different:

  • Cancer types (epithelial versus mesenchymal)

  • Microenvironmental conditions (different matrix compositions)

  • Signaling contexts (presence/absence of growth factors)

• Domain-specific interactions: Different epitope-targeting CD151 antibodies can help determine which domains of CD151 mediate specific functions. Some antibodies may block tumor cell migration and invasion by enhancing CD151-mediated stabilization of integrin complexes, resulting in firm cell-matrix adhesion and reduced motility .

• Temporal studies: CD151 antibodies can track changes in CD151 expression and function during different stages of tumor progression, from primary tumor growth to metastatic colonization.

• Modifier studies: CD151 antibodies can be used alongside manipulations of potential modifiers (e.g., different integrins, growth factor receptors) to identify factors that determine whether CD151 promotes or inhibits tumor progression.

Research findings indicate that CD151 overexpression correlates with increased metastatic propensity in some studies , while other reports suggest an inhibitory function in invasion and metastasis, possibly due to sustained adhesion to the extracellular matrix reducing tumor cell locomotion . These contradictory findings highlight the complexity of CD151 function and the need for careful experimental design when using CD151 antibodies in cancer research.

What technical considerations are important when using CD151 antibodies for immunoprecipitation of protein complexes?

Immunoprecipitation (IP) of CD151-containing protein complexes presents unique technical challenges due to the nature of tetraspanin interactions. Key considerations include:

• Detergent selection is crucial: The choice of detergent dramatically affects which interactions are preserved:

  • Mild detergents (Brij 97, CHAPS): Preserve tetraspanin-enriched microdomains and allow detection of CD151-integrin-Met complexes

  • Stringent detergents (Triton X-100, SDS): Disrupt most tetraspanin interactions

• Antibody validation for IP: Not all CD151 antibodies work effectively for immunoprecipitation. Research indicates that currently available antibodies may not allow efficient purification of CD151 immunocomplexes in certain cell lines like A549, necessitating model system selection based on high CD151 expression (such as GTL16 carcinoma cells) .

• Sequential IP protocols: For detecting ternary complexes (CD151-Met-β4), sequential immunoprecipitation can be more informative than single-step IP:

  • First IP: Isolate CD151 complexes

  • Second IP: Re-immunoprecipitate with anti-Met or anti-β4 antibodies

• Cross-linking approaches: Chemical cross-linking prior to cell lysis can stabilize transient or weak interactions involving CD151.

• Controls for specificity: Appropriate controls are essential:

  • CD151-knockdown cells as negative controls

  • Isotype control antibodies to identify non-specific binding

  • CD151 re-expression experiments to confirm specificity

Research has confirmed that CD151 immunocomplexes can contain both Met and β4 integrin, suggesting the formation of a ternary complex that can only be isolated using mild membrane detergents that preserve tetraspanin-enriched microdomains .

How can CD151 antibodies be used to study the role of CD151 in HGF-induced cell proliferation and survival?

CD151 plays a critical role in HGF-induced cell proliferation and survival, and CD151 antibodies can help elucidate these mechanisms through several experimental approaches:

• Proliferation assays: CD151 antibodies can be used to correlate CD151 expression with cell proliferation rates in response to HGF stimulation. Research has demonstrated that the proliferative response to HGF is impaired in CD151-deficient cancer cells, suggesting that CD151 has a role in signaling pathways controlling tumor cell growth .

• Soft agar colony formation: CD151 antibodies can help assess the role of CD151 in anchorage-independent growth, a hallmark of transformed cells. Studies have shown that CD151-deficient cells form significantly fewer foci upon HGF stimulation compared to control cells in soft agar assays .

• Anoikis resistance analysis: CD151 antibodies can be used in conjunction with anoikis assays to determine how CD151 contributes to cell survival in the absence of attachment. Research has shown that HGF stimulation efficiently protects control cells from anoikis but not CD151-deficient cells .

• Signaling pathway dissection: CD151 antibodies can be used alongside phospho-specific antibodies to determine how CD151 affects HGF-induced signaling cascades:

  • CD151 knockdown reduces HGF-triggered activation of MAPK but not AKT signaling

  • CD151 is necessary for HGF-induced phosphorylation of β4 integrin and subsequent Grb2-Gab1 association

The methodological data obtained from these experiments suggest that CD151 controls Met-dependent neoplastic growth by enhancing receptor signaling through β4 integrin-mediated pathways, independent of cell-substrate adhesion .

What approaches can researchers use to distinguish between direct and indirect effects of CD151 antibodies in experimental systems?

Determining whether observed effects of CD151 antibodies are due to direct inhibition of CD151 function or indirect effects requires careful experimental design:

• Comparison with genetic approaches: Results from CD151 antibody treatments should be compared with those from genetic manipulation (siRNA, shRNA, CRISPR/Cas9) of CD151. Research has shown that RNAi-mediated silencing of CD151 expression in cancer cells impairs HGF-driven proliferation, anchorage-independent growth, protection from anoikis, and tumor progression in xenograft models .

• Domain-specific antibody panels: Using multiple CD151 antibodies that target different epitopes can help identify which domains of CD151 mediate specific functions.

• Rescue experiments: Expressing CD151 variants resistant to antibody binding can determine whether observed effects are specifically due to CD151 inhibition. Studies have shown that exogenously re-establishing the expression of CD151 in gene-deficient cells partially restored HGF-induced protection from anoikis .

• Dose-response studies: Titrating antibody concentrations can distinguish between specific and non-specific effects.

• Isotype controls: Using isotype-matched control antibodies helps rule out Fc receptor-mediated or other non-specific effects.

• Timing experiments: Applying CD151 antibodies at different time points relative to stimulation can differentiate between effects on complex formation versus signaling propagation.

Research indicates that CD151 forms a molecular bridge between Met and β4 integrin, and this function can be disrupted by both antibody blocking and gene silencing approaches, suggesting direct mechanistic effects rather than indirect consequences .

How should researchers optimize CD151 antibody-based detection methods for low-abundance CD151 expression?

Detecting low-abundance CD151 expression presents technical challenges that can be addressed through several optimization strategies:

• Signal amplification methods:

  • Tyramide signal amplification for immunohistochemistry/immunofluorescence

  • High-sensitivity chemiluminescent substrates for Western blotting

  • Quantum dot conjugates for enhanced fluorescence detection

• Enrichment approaches:

  • Immunoprecipitation before Western blotting

  • Cell sorting to isolate CD151-positive subpopulations

  • Membrane fractionation to concentrate tetraspanin-enriched microdomains

• Alternative detection platforms:

  • Proximity ligation assay (PLA) for detecting protein-protein interactions involving CD151

  • Single-molecule detection methods

  • Mass spectrometry-based approaches following immunoprecipitation

• Technical optimization:

  • Extended antibody incubation times

  • Optimized blocking conditions to reduce background

  • Use of monovalent antibody fragments to improve tissue penetration

• Controls for validation:

  • CD151-overexpressing positive controls

  • CD151 knockout negative controls

  • Standard curves with recombinant CD151 protein

When working with samples where CD151 is expressed at low levels, consistency in sample processing and detection protocols is essential for reliable results. Researchers should also consider that CD151 expression may vary depending on cell type, culture conditions, and disease state .

What are common pitfalls when using CD151 antibodies in experimental research and how can they be addressed?

Researchers may encounter several challenges when working with CD151 antibodies. Here are common pitfalls and their solutions:

Research indicates that currently available antibodies may not allow efficient purification of CD151 immunocomplexes in certain cell lines like A549, suggesting that model system selection is crucial for successful experiments .

How can researchers optimize CD151 antibody-based assays for investigating CD151's role in tumor progression and metastasis?

To effectively study CD151's complex role in tumor progression and metastasis with antibody-based approaches, researchers should consider these optimization strategies:

• Model system selection:

  • Choose cell lines with appropriate CD151 expression levels

  • Consider using patient-derived xenografts for greater clinical relevance

  • Select models where CD151-dependent phenotypes have been validated

• Functional assay optimization:

  • For invasion assays: Optimize matrix composition and density

  • For migration studies: Use appropriate chemoattractants (e.g., HGF for Met-dependent studies)

  • For metastasis models: Consider organ-specific metastasis models relevant to CD151 function

• Imaging approaches:

  • For visualizing CD151 in metastatic sites: Optimize antigen retrieval protocols for tissue sections

  • For tracking CD151-positive cells: Consider xenografts with fluorescently labeled CD151

• Combination approaches:

  • Use CD151 antibodies in conjunction with integrin or Met pathway inhibitors

  • Combine CD151 detection with markers of epithelial-mesenchymal transition

  • Pair CD151 antibodies with matrix metalloproteinase activity assays

• Controls and validation:

  • Include tissue-matched non-metastatic controls

  • Validate findings across multiple cancer types

  • Confirm antibody specificity in each experimental system

Research has demonstrated that a CD151-specific antibody can prevent tumor cell invasion and metastasis by modulating cell-substrate adhesion, highlighting the potential therapeutic application of CD151 antibodies beyond their research utility .

What criteria should researchers use when selecting CD151 antibodies for specific research applications?

Selecting the appropriate CD151 antibody for a particular application requires consideration of several key criteria:

• Epitope specificity:

  • Antibodies targeting different domains of CD151 may reveal distinct functions

  • Extracellular domain antibodies are suitable for blocking experiments and flow cytometry

  • Intracellular domain antibodies may be better for certain Western blot applications

• Validation status:

  • Look for antibodies validated specifically for your application of interest

  • Consider antibodies validated in knockout/knockdown systems

  • Prioritize antibodies with published validation in peer-reviewed literature

• Clone characteristics:

  • Monoclonal antibodies (e.g., clone 50-6) provide consistent specificity

  • Polyclonal antibodies may offer higher sensitivity but less specificity

  • Consider species cross-reactivity if working with animal models

• Technical specifications:

  • For in vivo applications: Select low endotoxin preparations (<1.0 EU/mg)

  • For imaging: Consider brightness, photostability of conjugated fluorophores

  • For therapeutic studies: Consider antibody isotype (e.g., IgG1 k) for effector functions

• Application-specific requirements:

  • For IP: Ability to recognize native protein in mild detergent conditions

  • For IHC: Compatibility with fixation methods

  • For FACS: Brightness of conjugated fluorophore

• Commercial considerations:

  • Lot-to-lot consistency

  • Documentation of validation data

  • Technical support availability

Research suggests that different CD151 antibodies may have distinct functional effects, with some enhancing CD151-mediated stabilization of integrin complexes while others disrupt these interactions, highlighting the importance of careful antibody selection based on experimental goals .